Strs Ohio Has $627,000 Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Strs Ohio grew its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 94.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,800 shares of the biotechnology company’s stock after buying an additional 3,300 shares during the quarter. Strs Ohio’s holdings in Blueprint Medicines were worth $627,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Blueprint Medicines by 0.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,414 shares of the biotechnology company’s stock valued at $3,451,000 after buying an additional 145 shares in the last quarter. Diversified Trust Co raised its position in shares of Blueprint Medicines by 2.9% in the 3rd quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock valued at $563,000 after buying an additional 318 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Blueprint Medicines by 63.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 329 shares in the last quarter. Los Angeles Capital Management LLC raised its position in shares of Blueprint Medicines by 2.5% in the 3rd quarter. Los Angeles Capital Management LLC now owns 14,493 shares of the biotechnology company’s stock valued at $728,000 after buying an additional 355 shares in the last quarter. Finally, Arizona State Retirement System increased its position in Blueprint Medicines by 2.2% during the 3rd quarter. Arizona State Retirement System now owns 17,217 shares of the biotechnology company’s stock worth $865,000 after purchasing an additional 369 shares in the last quarter.

Blueprint Medicines Trading Up 2.5 %

NASDAQ:BPMC opened at $93.00 on Friday. The firm’s fifty day moving average is $90.79 and its 200-day moving average is $78.80. The company has a debt-to-equity ratio of 1.60, a quick ratio of 3.66 and a current ratio of 3.76. Blueprint Medicines Co. has a 52 week low of $43.89 and a 52 week high of $101.00. The firm has a market cap of $5.69 billion, a P/E ratio of -11.12 and a beta of 0.63.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The company had revenue of $71.96 million for the quarter, compared to analyst estimates of $67.34 million. During the same period in the prior year, the firm posted ($2.65) EPS. The company’s quarterly revenue was up 85.5% on a year-over-year basis. Equities analysts expect that Blueprint Medicines Co. will post -5.41 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the transaction, the director now directly owns 176,050 shares of the company’s stock, valued at $15,365,644. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Christopher K. Murray sold 5,000 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total transaction of $500,000.00. Following the transaction, the insider now directly owns 24,495 shares of the company’s stock, valued at $2,449,500. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey W. Albers sold 25,073 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the transaction, the director now owns 176,050 shares in the company, valued at approximately $15,365,644. The disclosure for this sale can be found here. Insiders have sold a total of 92,289 shares of company stock valued at $8,314,163 over the last ninety days. 3.88% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BPMC. HC Wainwright reiterated a “buy” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research report on Friday. Stifel Nicolaus upped their price objective on shares of Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday. Wedbush reiterated an “outperform” rating and set a $110.00 price objective on shares of Blueprint Medicines in a research report on Friday. JMP Securities reiterated a “market outperform” rating and set a $114.00 price objective on shares of Blueprint Medicines in a research report on Wednesday, April 10th. Finally, Citigroup upped their price objective on shares of Blueprint Medicines from $54.00 to $65.00 and gave the stock a “sell” rating in a research report on Friday, February 16th. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $91.57.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.